Kyverna Therapeutics (KYTX) Operating Expenses (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Operating Expenses data on file, last reported at $41.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 12.74% year-over-year to $41.4 million; the trailing twelve-month figure through Mar 2026 stood at $163.8 million (up 1.95% YoY), and the FY2025 full-year result was $169.8 million, up 19.09% from the prior year.
• Operating Expenses for Q1 2026 stood at $41.4 million, up from $39.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $47.4 million in Q1 2025 and bottomed at $11.4 million in Q1 2023.
• The 4-year median for Operating Expenses is $38.7 million (2025), against an average of $32.0 million.
• The widest annual swing landed in 2024, when Operating Expenses soared 156.51%; it then dropped 12.74% in 2026.
• A 4-year view of Operating Expenses shows it stood at $21.4 million in 2023, then surged by 91.99% to $41.0 million in 2024, then fell by 4.29% to $39.3 million in 2025, then climbed by 5.31% to $41.4 million in 2026.
• The last three Operating Expenses figures came in at $41.4 million (Q1 2026), $39.3 million (Q4 2025), and $38.7 million (Q3 2025), per Business Quant data.

Peer Comparison